Why Is TG THERAPEUTICS INC (TGTX) Stock Moving Today?

TGTX stock is moving 6.1% higher in Friday trading after building a base and testing a key moving average. The biotech stock is rebounding from an earnings sell-off in early August and has drawn speculation about potential acquisition interest. Recent updates to sales guidance and a price target increase from JPMorgan have also contributed to the upward momentum.

What Happened

TGTX stock opened at $54.45 and climbed to a session high of $55.94 before settling at $55.71 in late afternoon trading. The stock has traded between $52.00 and $55.94 during the session. The move follows a recent earnings report where the company posted Q2 revenue of $240.335 million, beating estimates, but EPS of $0.05 fell short of the $0.33 forecast. Despite the earnings miss, TGTX raised its FY2026 sales guidance to $950 million, exceeding the current estimate of $942.37 million. JPMorgan has maintained an overweight rating on the stock and raised its price target to $72. Meanwhile, traders are speculating that multiple parties may be interested in acquiring TG Therapeutics.

What The Data Shows

TGTX has traded within a 52-week range of $26.76 to $59.30 and has seen 1.3 million shares change hands so far, which is 0.6 times the 3-month daily average. The stock has experienced unusual options activity, with $629,000 in call premium traded and no put premium. The largest single print was $418,000. On the 52-week tape, the stock printed 22 fresh 52-week highs and three 52-week lows on August 24. Over the last eight sessions, the stock moved -7.9% from $53.48 to $49.23. Congressional transactions show two buys and two sells in the last 90 days, with the most recent filing on July 1.

What To Watch

TG Therapeutics is not scheduled to report earnings in the near term. Investors should monitor the breadth of institutional and retail coverage as the stock continues to trade near key technical levels and amid speculation of acquisition interest.